From: Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
Treatment | Efficacy | Prophylactic | Therapeutic | Status | References |
---|---|---|---|---|---|
Vaccines | Â | Â | Â | Â | Â |
DNA vaccines | Rodents and NHPs | Yes | Unknown | Phase I clinical trails | |
Adenovirus | Rodents and NHPs | Yes | Unknown | Phase I clinical trails | |
rVSV-EBOV | Rodents and NHPs | Yes | Yes | Experimental | |
HPIV3-EBOV | Rodents and NHPs | Yes | Unknown | Experimental | [70] |
EBOV-VLPs | Rodents and NHPs | Yes | Unknown | Experimental | [71] |
Replication-deficient ZEBOV | Rodents | Yes | Unknown | Experimental | [72] |
Antivirals | Â | Â | Â | Â | Â |
rhAPC | Partial in NHPs | Unknown | Yes | Licensed* | [75] |
rNAPc2 | Partial in NHPs | Yes | Yes | Phase II clinical trials†| [76] |
FGI-103, FGI-104 and FGI-106 | Rodents | Yes | Yes‡ | Experimental | |
Antisense oligonucleotides | Rodents and NHPs | Yes | Yes | Experimental |